"Intellia's Lonvo-z Shows Promising Results in Hereditary Angioedema Patients"

Intellia Therapeutics lonvo-z demonstrates significant efficacy in treating hereditary angioedema, achieving remarkable kallikrein reduction and offering hope for long-term patient relief.

• In a clinical trial involving 32 patients, 97% reported being attack-free and long-term prophylaxis (LTP)-free after receiving a 50 mg dose of lonvo-z.
• Among the initial 11 patients who received the 50 mg dosage in Phase 2, 10 maintained an attack-free and LTP-free status, showcasing the potential of this genome editing therapy.
• The study observed a favorable tolerability profile of lonvo-z, with no new long-term risks reported during up to three years of patient follow-up.